FUNDAMENTALS · Fundamentals · TW Basic Materials

CH Biotech R&D (6534) Fundamentals 2026 — P/E 19.2x, Revenue Analysis | SniperIQ

CH Biotech R&D (6534) is a TW-listed Basic Materials company in Agricultural Inputs with a market capitalization of NT$9.2B, trading at NT$91.70 on the TAI. This SniperIQ fundamentals page covers CH Biotech R&D's valuation (P/E 19.2x, P/B 3.5x), profitability (net margin 26.8%), revenue (NT

.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$9.2B
P/E (TTM)19.2x
Net Margin26.8%
Revenue (FY25)NT
.8B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is CH Biotech R&D's market cap?

CH Biotech R&D (6534) has a market capitalization of approximately NT$9.2B, trading at NT$91.70 on the TAI. Market cap moves with the live share price.

What is CH Biotech R&D's P/E ratio?

CH Biotech R&D's trailing twelve-month P/E ratio is 19.2x, with a price-to-book (P/B) of 3.5x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.

How profitable is CH Biotech R&D?

CH Biotech R&D runs a net profit margin of 26.8%, a gross margin of 81.4%, and an operating margin of 36.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does CH Biotech R&D generate?

CH Biotech R&D reported revenue of NT

.8B for fiscal year 2025, with net income of NT$464M and earnings per share (EPS) of 4.51. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does CH Biotech R&D pay a dividend?

CH Biotech R&D offers a trailing dividend yield of about 5.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is CH Biotech R&D financially healthy?

CH Biotech R&D carries a debt-to-equity ratio of 0.23x and a current ratio of 1.08x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is CH Biotech R&D a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CH Biotech R&D (6534) the key facts are: market cap NT$9.2B, P/E 19.2x, revenue NT

.8B, 52-week range 77.6-123.5. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.

Track CH Biotech R&D's full fundamentals live

Get CH Biotech R&D's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.